Clinical Trial Update: Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating PT027 versus PT007 given as-needed in youths aged 12 to <18 with asthma; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• PT007
• PT027

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: RECRUITING